Group or individual brain training for memory problems after breast cancer chemotherapy
Tests thinking-skill training for cognitive problems in women having breast cancer treatment.
Plain-language title generated from the registry record
Registry title: Effects of a Group Versus Individual Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment
Key facts
- Where
- Salamanca, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed breast cancer who are starting cancer treatment. It tests a cognitive training program for memory and thinking problems linked to treatment.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Recent, newly diagnosed breast cancer, confirmed by tissue examination, at the start of cancer treatment
- Earlier treatment
- Must be starting cancer treatment; cannot be in another cognitive stimulation program
Main reasons for not taking part
- Cannot read or write, or has a major problem understanding language
- Tumor of the central nervous system
- Taking part in another cognitive stimulation program
- Diagnosed neurocognitive disorder as defined in the DSM-V
Read by machine on 9 November 2026.
Where in Spain
- Juan LuisSalamanca, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Salamanca
- Trial code
- NCT07165912
- Record updated
- 28 April 2026
- Original description
Introduction: The significant improvement in breast cancer survival, largely attributable to biomedical and technological progress, makes it increasingly necessary to investigate the secondary effects linked to this pathology. Among these, cancer-related cognitive impairment (CRCI) stands out as one of the most frequent yet frequently overlooked complications.Read full original descriptionShow less
Effects of a Group Versus Individual Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment
Introduction: The significant improvement in breast cancer survival, largely attributable to biomedical and technological progress, makes it increasingly necessary to investigate the secondary effects linked to this pathology. Among these, cancer-related cognitive impairment (CRCI) stands out as one of the most frequent yet frequently overlooked complications.
Objective: To evaluate the impact of a structured cognitive training program on the management of CRCI in patients with breast cancer receiving active treatment.
Methodology: A randomized controlled clinical trial will be conducted with two arms: an Intervention Group (IG) and a Control Group (CG). The study will include patients with a recent diagnosis of breast cancer. Based on sample size calculations, 50 participants will be recruited-25 per group-to detect a minimum difference of 2.95 points on the MoCA (Montreal Cognitive Assessment), a tool commonly used to assess cognitive performance. All participants will receive an informational leaflet aligned with the latest WHO recommendations for preventing cognitive decline. In addition, the IG will complete an individualized cognitive training (CT) program focused on everyday cognitive skills (EC). The program will provide a dossier with 80 training sessions, structured into four phases (P1-P4) of 20 activities each, to be implemented monthly. Baseline assessments and a follow-up four months after the intervention will be carried out in both groups. Variables collected will include sociodemographic and clinical data, as well as outcome measures for cognitive status (MoCA), everyday cognition (PECC), anxiety levels (Hamilton scale), functional capacity (LB), sleep quality (PSQI), quality of life (ECOG), and subjective memory complaints (FACT-COG).
Impact: Findings from this study could support the development of targeted cognitive rehabilitation strategies and the implementation of clinical protocols for individuals undergoing breast cancer treatment. By addressing CRCI-an underrecognized but increasingly prevalent issue given rising survival rates-these interventions may contribute to improving patients' overall quality of life.
Inclusion: Being an adult (18 years or older). Having a recent histopathological diagnosis of newly diagnosed breast cancer and starting oncological treatment; Being fully capable of performing daily functions. Willingness to voluntarily participate in the study and signing the informed consent.
Exclusion: Clinical diagnosis of a neurocognitive disorder as defined in the DSM-V; Lack of literacy skills or significant language comprehension deficit. Diagnosis of a Central Nervous System tumor or participation in another cognitive stimulation program; Withdrawal Criteria:; Dropping out of the program or not completing the final evaluation.